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Abstract
Background: Delayed presentation of pulmonary TB (PTB) patients for treatment from onset of symptoms remains
a threat to controlling individual disease progression and TB transmission in the community. Currently, there is
insufficient information about treatment delays in Zimbabwe, and we therefore determined the extent of patient
and health systems delays and their associated factors in patients with microbiologically confirmed PTB.
Methods: A structured questionnaire was administered at 47 randomly selected health facilities in Zimbabwe by
trained health workers to all patients aged ≥18 years with microbiologically confirmed PTB who were started on
TB treatment and entered in the health facility TB registers between 01 January and 31 March 2013. Multivariate
logistic regression was used to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CIs) for associations
between patient/health system characteristics and patient delay >30 days or health system delay >4 days.
Results: Of the 383 recruited patients, 211(55%) were male with an overall median age of 34 years (IQR, 28-43). There
was a median of 28 days (IQR, 21-63) for patient delays and 2 days (IQR, 1-5) for health system delays with 184 (48%)
and 118 (31%) TB patients experiencing health system delays >30 days and health system delays >4 days respectively.
Starting TB treatment at rural primary healthcare vs district/mission facilities [aOR 2.70, 95% CI 1.27-5.75, p = 0.01] and
taking self-medication [aOR 2.33, 95% CI 1.23-4.43, p = 0.01] were associated with encountering patient delays.
Associated with health system delays were accessing treatment from lower level facilities [aOR 2.67, 95% CI 1.18-6.07,
p = 0.019], having a Gene Xpert TB diagnosis [aOR 0.21, 95% CI 0.07-0.66, p = 0.008] and >4 health facility visits prior to
TB diagnosis [(aOR) 3.34, 95% CI 1.11-10.03, p = 0.045].
Conclusion: Patient delays were longer and more prevalent, suggesting the need for strategies aimed at promoting
timely seeking of appropriate medical consultation among presumptive TB patients. Health system delays were
uncommon, suggesting a fairly efficient response to microbiologically confirmed PTB cases. Identified risk factors
should be explored further and specific strategies aimed at addressing these factors should be identified in order
to lessen patient and health system delays.
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Background
Tuberculosis remains an infectious disease of public
health concern with the World Health Organisation
(WHO) declaring it a global public health emergency in
1993 [1]. There has been a global increase in notified TB
cases since then from an estimated 7-8 million cases to
9 million cases in 2013 [1]. In sub-Saharan Africa, the
resurgence of TB has been attributed mostly to the HIV
pandemic, and this has been felt most strongly in the
southern part of the continent [2]. Providing treatment
with anti-tuberculosis drugs through the directly ob-
served treatment short course (DOTS) has greatly
assisted most national tuberculosis control programmes
in curing TB, and as a result it is estimated that from
2000 to 2013, 37 million lives have been saved [1]. How-
ever, the continued spread of TB can partly be attributed
to delayed or undiagnosed TB and this in turn has also
been shown to be associated with increased mortality [3].
The severity of disease and the likelihood of a TB in-
fected individual infecting another person is highest in
those with microbiologically confirmed pulmonary TB
(PTB) in comparison with other types of TB such as
smear-negative pulmonary TB and extra-pulmonary TB
[4]. Moreover, the high burden of HIV co-infection
results in a rapid increase in the number of tuberculosis
patients in the community [4]. Zimbabwe has a high
burden of TB/HIV co-infection, which was recorded at
69% in 2013 [1]. In 2013 prevalence estimates of TB
morbidity (including HIV/TB co-infections) were 409
(235-630) cases per 100,000 population whilst mortality
estimates (including HIV/TB deaths) were 153 (121-189)
cases per 100,000 population [1].
Given this, early diagnosis and immediate initiation of
TB treatment are therefore essential for an effective TB
control programme in order to prevent further disease
progression at the individual level and transmission
within the community. A systematic review of 52 studies
on the length of treatment delays by Sreeramareddy et al
[5] showed that average patient delays and health system
delays were similar (28.7 versus 25 days) and the trend
was similar when stratified into low and high income
countries. Other systematic reviews by Storla et al [6]
and Finnie et al [7] showed varying factors associated
with TB treatment delays but both highlighted the
importance of how uptake of measures to shorten these
delays may reduce infectious cases and improve TB con-
trol. In Finnie et al’s [7] systematic review which was
specific to sub-Saharan Africa, consulting traditional
leaders first and longer travel time were consistently
associated with patient health system delays among
other factors. In the Zimbabwe National TB programme,
there is insufficient knowledge on the extent of total TB
treatment delay and whether such delay is mostly attrib-
utable to patient delay or health system delay. The aim
of this study was therefore to assess the length of patient
and health system delays among TB patients in Zimbabwe
and their associated risk factors.
Methods
Study design
This was a descriptive cross-sectional study.
Study participants and sampling
We used a two-stage random sampling design. In the
first stage, 4 of the country’s 10 provinces were ran-
domly selected, whilst in the second stage, 3 districts
were randomly selected in each province. In the third
stage, 4 health facilities were randomly selected from all
health facilities that registered ≥30 smear-positive PTB
cases per month in each district. In total, 47 health facil-
ities were included in the study of which 3 were provin-
cial hospitals, 15 were district/mission hospitals, 10 were
urban clinics and 19 were rural primary health care
facilities.
All patients aged ≥ 18 years with microbiologically
confirmed PTB and who were started on TB treatment
and entered in the TB registers from these facilities be-
tween 01 January and 31 March 2013 were sequentially
recruited in the study after verbal consent. The diagno-
sis and confirmation of TB was either by sputum-smear
microscopy for acid-fast bacilli or GeneXpert MTB/RIF
assay. Using Dobson’s formula, a minimum sample size
of 260 study participants was required to estimate the
proportion with patient delays >30 days given a 95%
confidence interval (CI) with a 5% margin of error,
based on 83% of patients experiencing patient delay
>30 days as derived from a study by Odusanya et al [8]
and an 80% response rate.
TB diagnosis under the National TB program
In Zimbabwe, TB treatment services are integrated
with general health services at all health facilities in
the country. When patients present with TB symptoms
at a health facility, they are recorded in the TB suspect
register and have their sputum examined by direct
smear microscopy looking for acid-fast bacilli with a
Ziehl-Neelsen stain. Sputum specimens are sent to TB
diagnosing centres for sputum-smear microscopy
which are often located at selected primary level health
facilities (microscopy centres) and all secondary level
health facilities (district or mission hospitals) in each
district and all tertiary level (provincial) hospitals at
the provincial level. In urban areas, TB diagnosing
centres are located at selected municipal polyclinics.
Smear-positive PTB cases are those with sputum
smears positive for acid-fast bacilli [9]. Recently, Gene
Xpert is being recommended as the initial TB diagnosis
test among presumptive TB patients who are HIV-
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infected or who have risk factors for drug-resistant TB
although it is not available at all TB diagnosing centres.
In patients who are known to be HIV-negative and/or
who have no risk factors for DR-TB, sputum smear
microscopy remains the diagnostic method of choice.
Patients with smear-positive sputum or a positive re-
sult from Gene Xpert are classified as having micro-
biologically confirmed PTB and have their results
communicated to their respective health facilities by
telephone. Upon receiving this communication, these
patients are traced in the community by a village
health worker (VHW) or an environmental health
technician (EHT).
Once traced, these patients are referred back to their
nearest health facility where they are registered in the
health facility daily observed treatment (DOT) register
and are started on anti-TB treatment. All presumptive
and confirmed TB patients are offered HIV counselling
and testing (opt-out provider-initiated) and those con-
firmed HIV-positive are provided with [10] HIV treat-
ment and care in the form of cotrimoxazole preventive
therapy (CPT) and antiretroviral therapy (ART), pro-
vided there is no contra-indication [11].
Data variables, source of data and data collection
A one-day data collection training exercise was con-
ducted prior to piloting of the questionnaire. Data were
collected using a structured questionnaire adapted from
WHO [12], and this was administered by selected health
workers in the selected health facilities. Variables that
were abstracted from TB registers included: date of col-
lection of the sputum specimens, type of TB, name of
referring health facility, TB treatment start date, sex and
age of the patient. TB registration numbers and TB sus-
pect numbers were collected as patient identifiers in
place of patient names. The structured questionnaires
were administered to all microbiologically confirmed
PTB patients upon commencing TB treatment or dur-
ing review visits within 1 week of commencing TB treat-
ment. Questionnaires were also translated into the 2
local languages (Shona and Ndebele) for those who were
not conversant with English. Informed verbal consent
was sought prior to the interview and participants were
allowed to withdraw from the interviews whenever they
pleased.
Variables collected in the questionnaire about timing
and treatment delays included:- date of onset of any TB
symptoms, date of first encounter with a health worker
and number of visits to a health facility prior to starting
treatment. Information on the first encounter with a
health worker and the number of visits to the health
facility was verified wherever possible by looking through
the patient’s case notes and their TB treatment card.
Study definitions
This study focused on total delay which was stratified
into patient delay and health care system delay. These
terms were defined as follows:
Patient delay
The time period in days between the onset of TB
symptoms and the patient’s first contact with a health
worker of >30 days [7,13,14]. Contact with a health
worker refers to a nurse or medical doctor at a public
health facility (which are the only institutions pro-
viding TB treatment) and this excludes pharmacists,
private practitioners or traditional healers. Onset of TB
symptoms was defined as the first experience of any
symptoms suggestive of TB (cough, fever, weight loss,
haemoptysis, fatigue, night sweats).
Health care system delay
The time period in days between the date of first contact
with a health worker and the date of start of TB treat-
ment of >4 days. This is under the assumption that
laboratory turn-around times for sputum samples are
expected to be less than 72 hours and are coupled with
immediate tracing of patients for start of TB treatment
for purposes of infection control.
Statistical analysis
Patient data collected in the structured report form
were coded and double entered by three independent
data entry clerks into EpiData version 3.1 and later
cleaned for errors and analysed using STATA, version
12.1 (Stata Corporation, College Station, Texas). Data
were weighted prior to analysis to account for unequal
probabilities of selection and to also account for the
clustering effect of the sample design. Patient and
health care system delays were first summarised and
presented as the median (interquartile range) number
of days. Patient delay was then categorised as patient
delay >30 days whilst health system delay was cate-
gorised as health system delay >4 days and these were
used for the univariate analysis. Associations between
patient characteristics and both types of delay were
determined by the chi-square test or alternatively the
Fischer’s Exact test if numbers were small. Logistic
regression was used to calculate adjusted odds ratios
(aOR) and their respective 95% confidence intervals
for factors associated with patient delay and health
system delay. All patient characteristics with p-values
< 0.25 or those thought to be biologically plausible
were included in both the univariate and multivariate
logistic regression models. P-values of less than 0.05
were considered statistically significant.
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Ethics and approval
Ethics approval was obtained locally from the Medical
Research Council of Zimbabwe (MRCZ) and also the
Ethics Advisory Group (EAG) for the International Union
Against Tuberculosis and Lung Disease (IUATLD).
Results
Patient characteristics
During the 3-month study period, all 383 interviewed
patients gave voluntary consent to participate in the
survey of whom the majority, 211 (55%) were male
(Table 1). Overall median age of study participants
was 34 years (IQR, 28-43). Most patients (62%) were
recruited upon starting TB treatment from either
district or mission hospitals. The majority of these
patients, 280 (75%), started TB treatment at TB diag-
nosing centres were they had also been diagnosed.
Tuberculosis diagnosis was mainly by sputum-smear
microscopy (95%). Nearly all patients (98%) had been
HIV-tested: there were 230 (62%) who were HIV-
infected. Most patients (70%) resided in rural areas,
unemployment was high (62%) and more than half
(55%) had attained secondary school education or
higher.
Patient delays and associated factors
There was a median of 28 days for patient delays (IQR,
21-63). Of all recruited study participants, 184 (48%)
experienced patient delays >30 days in seeking TB treat-
ment services.
Table 2 shows factors associated with patient delay. In
comparison to patients starting TB treatment at district
or mission hospitals, those starting treatment at rural
primary health facilities were more likely [adjusted odds
ratio (aOR) 2.70, 95% confidence interval (CI) 1.27-5.75,
p = 0.01] to experience patient delays. On further ana-
lysis, those patients who started TB treatment at rural
facilities accessed traditional healers first more than
those accessing other types of health facilities although
the association was not statistically significant (14.2% vs.
8.4%, p = 0.192). The seeking of treatment first at private
practitioners was also similar for both those who were
treated at rural facilities and other types of health facil-
ities (7.8% vs. 7.5%, p = 0.937).
The likelihood of patient delays was higher for those
who took self medication when experiencing cough
symptoms [aOR 2.33, 95% CI 1.23-4.43, p = 0.01]. Those
taking between 30 minutes to an hour to reach their
DOT facility [aOR 0.43, 95% CI 0.22-0.83, p = 0.013] and
>1 hour [aOR 0.47, 95% CI 0.24-0.94, p = 0.032] were
both less likely to experience patient delays when com-
pared to those reaching the DOT facility in less than
30 minutes.
Health system delays and associated factors
There was a median of 2 days for health system delays
(IQR, 1-5). There were only 118 (31%) of all study
participants who encountered health system delays
>4 days. Table 3 shows factors associated with health
system delay >4 days. Health system delays were higher
among those 26-44 years old [aOR 3.30, 95% CI 1.16-
9.37, p = 0.025] and aged 45-54 years [aOR 3.57, 95%
CI 1.09-11.72, p = 0.036]. Being male and having TB
diagnosis done using GeneXpert were also associated
with less odds of health system delays i.e. [aOR 0.47,
95% CI 0.23-0.96, p = 0.038] and [aOR 0.21, 95% CI
0.07-0.66, p = 0.008] respectively. All those who had a
GeneXpert test done were HIV-infected individuals.
In addition, the odds of health system delays were
higher when starting treatment at urban municipal
clinics [aOR 6.9, 95% CI 2.41-19.82, p = 0.03] and rural
clinics [aOR 2.67, 95% CI 1.18-6.07, p = 0.019] although
these delays were not significantly higher for those
accessing treatment from non-TB diagnosing facilities
after multivariate analysis. Lastly, there were higher odds
of health system delays associated with encountering ≥4
health care visits in comparison to one healthcare visit
prior to starting TB treatment [aOR 2.24, 95% CI 1.02-
4.94, p = 0.045]. Further stratification of those with ≥4
healthcare visits by type of health-worker seen among
those experiencing health system delays showed that 8
(42%) had seen different health workers in the same
facility and 11 (58%) had seen different health workers
in different health facilities.
Total delays
Total delay among all recruited study participants was a
median of 36 days (IQR, 23-68). Figure 1 shows the dis-
tribution of total delays in weeks.
Discussion
In this study, we assessed the extent of both patient
and health system delays in accessing TB treatment
within public health facilities under the Zimbabwe
National Tuberculosis Programme. The median patient
delay was 28 days and this is similar to findings from
other African countries such as Ghana [15] and South
Africa [16] and slightly lower than reported findings
from other low income countries as reported in a
systematic review by Sreeramareddy et al [5]. The tak-
ing of self-medication for TB-related symptoms, as has
been found in other studies [17,18], was associated with
patient delay, although in general this practice was
uncommon amongst this patient population. Also
uptake of traditional medicine was not significantly
associated with patient or health system delays and
assuming there was no under-reporting, this practice
was uncommon despite the fact that more than two
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Table 1 Characteristics of tuberculosis patients in
Zimbabwe
Characteristics (N = 383) n N Weighted percent
(95% CI)
Age in years
18 – 25 53 383 13.9% (10.5-18.2)
26 – 44 244 383 63.8% (58.3-69.0)
45 – 54 54 383 14.2% (10.6-18.6)
≥55 31 383 8.1 (5.7-11.6)
Sex
Female 172 383 45.0% (39.5-50.6)
Male 211 383 55.0% (49.4-60.5)
Type of diagnostic test
Sputum microscopy 363 383 94.8% (93.0-96.2)
Gene Xpert 20 383 5.2% (3.8-7.0)
Type of health facility
Provincial hospital 18 383 4.7% (3.1-6.9)
District/mission hospital 237 383 61.8% (58.5-64.9)
Urban municipal 73 383 19.1% (16.7-21.8)
Rural primary healthcare facility 55 383 14.5% (11.4-18.2)
Diagnosing centre
Same as DOT facility 280 373 75.1% (71.8-78.2)
Different from DOT facility 93 373 24.9% (21.8-28.3)
Missing 10 383 2.6%
HIV tested
No 6 376 1.6% (0.8-3.4)
Yes 370 376 98.4% (96.6-99.2)
Missing 7 383 1.9%
HIV status
HIV-negative 140 370 37.9% (32.6-43.6)
HIV-positive 230 370 62.1% (56.4-67.4)
HIV + ve patient on CPT/ART prior
to TB treatment
No 72 230 31.2% (25.4-37.6)
Yes 158 230 68.8 (62.4-74.7)
Staying with anyone currently on
TB treatment
No 348 383 90.9% (86.3-95.3)
Yes 35 383 9.1% (6.3-13.1)
Education
More than secondary 20 382 5.3% (3.3-8.4)
Secondary 192 382 50.3% (45.0-55.6)
Primary 145 382 38.0% (33.1-43.1)
No education 25 382 6.5% (4.2-9.8)
Missing 1 383 0.4%
Employment status
Formal employment 40 379 10.7% (8.0-14.2)
Informal employment 105 379 27.6% (23.1-32.6)
Table 1 Characteristics of tuberculosis patients in
Zimbabwe (Continued)
Unemployed 234 379 61.8% (56.7-66.6)
Missing 4 383 1.0%
Residence
Urban 114 378 30.1% (26.1-34.5)
Rural 264 378 69.9% (65.6-73.9)
Missing 5 383 1.3%
History of smoking
Never smoked 269 380 70.7% (65.3-75.5)
Current smoker 26 380 6.8% (4.3-10.6)
Quit smoking 86 380 22.5% (18.3-27.4)
Missing 3 383 0.8%
History of alcohol use
Never 213 373 57.0% (51.4-62.4)
Current drinker 29 373 7.7% (5.5-10.6)
Quit alchohol use 132 373 35.3% (30.2-40.9)
Missing 10 383 2.6%
Previous contact with TB patient
No 210 383 54.8% (48.4-62.1)
Yes 173 383 45.2% (39.8-50.6)
Marital status
Married 225 380 59.3% (53.6-64.7)
Single 67 380 17.6% (13.7-22.4)
Divorced/separated 35 380 9.3% (6.6-12.9)
Widowed 52 380 13.8% (10.2-18.4)
Missing 3 383 0.8%
Took self medication from pharmacy
No 335 383 87.5% (84.0-90.3)
Yes 48 383 12.5% (9.7-16.0)
Took traditional medicine
No 348 383 90.8% (87.3-93.4)
Yes 35 383 9.2% (6.6-12.7)
Visited a private practitioner
No 354 383 92.4% (89.4-94.7)
Yes 29 383 7.6% (5.4-10.6)
Health care visits prior to diagnosis
1 173 378 45.6% (40.2-51.1)
2 121 378 31.9% (26.9-37.3)
3 40 378 10.5% (7.6-14.4)
≥4 45 378 12.0% (9.1-15.7)
Missing 5 383 1.2%
Time taken to reach health facility
<30 minutes 150 377 39.9% (35.1-44.8)
30mins - 1 hour 101 377 26.7% (21.9-32.0)
>1 hour 126 377 33.5% (28.6-38.8)
Missing 6 383 1.5%
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thirds of study participants resided in a rural setting.
This finding differs from findings from a meta-analysis
by Finnie et al [7] of other sub-Saharan African coun-
tries where taking of traditional medicine was consist-
ently found to be associated with patient delays.
Patients who started TB treatment at rural primary
healthcare facilities were more likely to experience
patient delays when compared to those who started at
district or mission hospitals. Literature from other
countries also indicates that an initial visit to a govern-
ment low-level health care facility [19-21] and rural
residence [14,16,22] are both associated with increased
patient delays in seeking TB treatment services. Whilst
the majority of our study participants were rural pa-
tients, distance to a DOT facility was not associated
with patient delay and in fact those taking a longer
time to reach a DOT facility were less likely to expe-
rience patient delays. The reasons for this finding are
not clear as other studies have found that long
distances to health facilities [7] and absence of trans-
port have contributed to poor and delayed uptake of
HIV care and treatment in co-infected patients [23].
It is likely that the patient delays among those with
shorter travel time to a health facility and accessing
treatment at lower-level health facilities are attributed to
these patients being less health conscious and seeking
treatment late in comparison to those who are more
health conscious who seek services sooner at higher-
level hospitals even though they may be further away.
Zimbabwe has a four-tiered referral health system and
district/mission hospitals which are at the second level
may be preferable to patients since they manage referral
cases not managed at primary care facilities which are
at the first level, as they have a staff complement of
medical doctors in addition to nursing staff. They also
provide specialized services to periphery first-level
health facilities within their district such as laboratory
services and ART initiation prior to decentralization of
ART initiations to lower-level health facilities. These
district/mission hospitals are also centrally located within
the district and therefore usually better resourced and
managed and generally further away from patients in
comparison to primary facilities, particularly in rural
settings.
Contrary to other published studies, gender [24],
education level [13] and old age [25,26] were not asso-
ciated with patient delays. In our study, HIV status
showed no association with patient or health system
delays, as has been found elsewhere [16,27].
In this study, the greater proportion of delay in seeking
TB treatment was a result of patient-related factors
rather than health system factors, a finding that is simi-
lar to that of other countries [8,17,28,29]. The median
health system delay was just 2 days, which is low in
comparison to findings from other studies done in both
intermediate [30,31] and high-burden TB [14,16,19]
settings. This encouraging finding highlights the effi-
ciency within the national TB programme of processes
that exist from sputum collection to sputum examin-
ation to diagnosis and the return of results to the health
worker and eventual transmission of information to the
patient which is followed by the initiation of the patient
on anti-TB treatment among microbiologically con-
firmed PTB cases.
Of note were the higher health system delays among
those receiving treatment at lower-level health facilities
and those with four or more health facility visits prior
to starting TB treatment. Primary health-care facilities
usually do not have TB diagnosing facilities on site and
therefore refer sputum samples to TB diagnosing cen-
tres at second-level health facilities thereby increasing
sputum turnaround times, especially in rural settings.
Whilst sputum transportation using motorbikes has
been established in some districts ranging from 2-day
to 1-week intervals, it remains ad-hoc in some places
and this needs improvement. In Zimbabwe, Gene Xpert
which is a more accurate and rapid diagnostic test [32],
has recently been recommended [33] and piloted as the
initial diagnostic test for HIV-infected persons in addition
to those with drug resistant TB risk factors as recom-
mended by WHO [34]. This explains why fewer health
system delays were noted for those HIV-infected patients
with TB diagnosed using the Gene Xpert MTB/RIF assay
compared to the conventional smear microscopy.
Those who had four or more visits had either seen dif-
ferent health workers in the same facility or different
health workers in different health facilities and this finding
Table 1 Characteristics of tuberculosis patients in
Zimbabwe (Continued)
Distance to health facility(in km)
≤5 122 331 36.8% (32.3-41.6)
6 – 15 64 331 19.5% (15.4-24.3)
16 – 30 55 331 16.5% (12.3-21.8)
≥30 90 331 27.2% (22.4-32.5)
Missing 52 383 13.7%
Difficulty in accessing transport
to health centre
No 322 383 84.2% (78.9-89.5)
Yes 61 383 15.8% (12.1-20.5)
Ever heard of TB before diagnosis
Yes 43 365 88.1% (83.6-91.5)
No 322 365 11.9% (8.5-16.4)
Missing 18 383 4.8%
NB: Percentages may not always add up to 100 because of rounding off error.
DOT = directly observed treatment; HIV = human immunodeficiency virus; CPT =
cotrimoxazole preventive therapy; ART = antiretroviral therapy, TB = tuberculosis.
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Table 2 Factors associated with patient delay in accessing TB treatment services
Characteristic (N = 383) Patient delay > 30 days*
n (%) OR (95% CI) Adjusted OR (95% CI)
Age in years
18 – 25 30 (55.8) Reference Reference
26 – 44 122 (50.0) 0.79 (0.41-1.53) 0.55 (0.25-1.19)
45 – 54 24 (43.9) 0.62 (0.26-1.46) 0.55 (0.21-1.43)
≥55 9 (29.4) 0.33 (0.12-0.88) 0.35 (0.10-1.24)
Sex
Female 80 (46.5) Reference Reference
Male 105 (49.7) 1.13 (0.72-1.78) 1.07 (0.59-1.96)
Type of health facility
District/mission hosp 95 (51.2) Reference Reference
Provincial hospital 10 (5.2) 1.77 (0.64-4.86) 1.82 (0.53-6.30)
Urban municipal clinic 45 (24.6) 2.45 (1.42-4.22) 1.78 (0.88-3.60)
Rural primary healthcare facility 35 (19.0) 2.61 (1.36-5.01) 2.70 (1.27-5.75)
HIV status
Not tested 2 (40.0) Reference Reference
HIV negative 63 (44.6) 1.21 (0.25-5.81) 1.01 (0.16-6.51)
HIV positive, not on ART 36 (51.0) 1.56 (0.32-7.66) 1.38 (0.22-8.77)
HIV positive, on ART/CPT 80 (50.5) 1.53 (0.32-7.30) 1.68 (0.26-10.77)
Staying with anyone currently on TB treatment
No 170 (48.9) Reference Reference
Yes 15 (41.7) 0.75 (0.35-1.61) 0.99 (0.79-1.23)
Education
More than secondary 10 (48.2) Reference Reference
Secondary 101 (52.7) 1.20 (0.43-3.31) 1.40 (0.45-4.37)
Primary 66 (44.8) 0.87 (0.31-2.45) 1.35 (0.39-4.74)
No education 9 (36.7) 0.62 (0.17-2.29) 1.10 (0.23-5.33)
Employment status
Formal employment 25 (61.2) Reference Reference
Informal employment 54 (51.5) 0.67 (0.33-1.39) 0.92 (0.37-2.27)
Unemployed 104 (44.3) 0.50 (0.26-1.00) 0.74 (0.30-1.85)
Residence
Urban 60 (52.8) Reference Reference
Rural 119 (46.2) 0.82 (0.53-1.26) 1.04 (0.80-1.33)
History of smoking
Never 131 (48.8) Reference Reference
Current smoker 10 (36.8) 0.61 (0.24-1.57) 0.59 (0.20-1.78)
Quit smoking 43 (50.3) 1.06 (0.63-1.80) 0.75 (0.35-1.62)
History of alcohol use
Never 98 (46.2) Reference Reference
Current drinker 12 (43.0) 0.88 (0.40-1.91) 1.19 (0.39-3.57)
Quit alcohol use 69 (52.3) 1.28 (0.78-2.08) 1.26 (0.61-2.64)
Previous contact with TB patient
No 100 (47.8) Reference Reference
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may highlight an important barrier to early diagnosis and
treatment of TB, especially among mobile populations
where each consecutive visit to a different health care
worker may be like a first time visit if the hospital or pa-
tient records are not properly scrutinised. This calls for an
important need to strengthen TB case diagnosis and man-
agement trainings among health workers to ensure that
information about investigations and management is ef-
fectively passed on from one health care worker to an-
other. In general, however, the majority of patients (78%)
had visited the health facility ≤ 2 times before the diagnosis
of TB was made, and this does suggest that the awareness
and knowledge of TB is high among health workers in a
high HIV-TB burden country like Zimbabwe. This high
awareness may relate to the high burden of disease in
Zimbabwe: in 2008 alone, TB cases contributed 30% of all
chronic out-patient disease conditions [35].
Unlike other studies done in urban settings [13,36,37]
our study includes a heterogenous population of TB
patients in Zimbabwe coming from different levels of the
healthcare system, from different regions and with a rural
and urban mix, and therefore is representative of the over-
all TB programme in Zimbabwe. Limitations of our study
include a possibility of recall bias of past events among
respondents relating to when they first encountered TB
symptoms. Health system delays may have shortened dur-
ing the time of the survey since the structured question-
naires were administered by health workers from the
selected health facilities. Our study could have failed to
capture information on confirmed TB cases that were
started on TB treatment but were not registered as shown
in a study conducted in one province of Zimbabwe in
which 43% of treated TB cases were not registered [38].
There is also a possibility that our patient sample
excluded vital information on those patients who may
have been suspected of TB or diagnosed of TB in the
private sector but did not go to public health facilities
despite being referred. This is given the background that
Table 2 Factors associated with patient delay in accessing TB treatment services (Continued)
Yes 84 (48.8) 1.03 (0.66-1.59) 0.96 (0.79-1.16)
Took traditional medicine
No 163 (46.8) Reference Reference
Yes 22 (62.4) 1.88 (0.84-4.20) 1.80 (0.76-4.28)
Took self-medication from pharmacy
No 140 (44.5) Reference Reference
Yes 45 (65.4) 2.35 (1.35-4.11) 2.33 (1.23-4.43)
First consulted private practitioner
No 166 (46.9) Reference Reference
Yes 19 (65.3) 2.14 (0.95-4.81) 1.47 (0.56-3.87)
Time taken to reach health facility
<30 minutes 89 (59.3) Reference Reference
30mins - 1 hour 40 (39.9) 0.45 (0.26-0.81) 0.43 (0.22-0.83)
>1 hour 54 (42.5) 0.51 (0.31-0.82) 0.47 (0.24-0.94)
Distance to health facility (in km)
≤5 66 (54.1) Reference Reference
6 – 15 28 (43.8) 0.66 (0.36-1.21) 1.14 (0.52-2.47)
16 – 30 27 (50.1) 0.85 (0.41-1.76) 1.85 (0.79-4.37)
≥30 39 (43.0) 0.64 (0.35-1.18) 1.39 (0.60-3.23)
Difficulty in accessing transport to health centre
No 150 (46.6) Reference Reference
Yes 35 (57.3) 1.51 (0.80-2.85) 0.66 (0.40-1.08)
Ever heard of TB before diagnosis?
No 18 (40.4) Reference Reference
Yes 156 (48.7) 1.40 (0.63-3.13) 1.16 (0.97-1.40)
Total 184 (48.3) - -
*Patient delay was defined as a period >30 days from onset of any TB symptom to date of first encounter with health worker.
HIV = human immunodeficiency virus; CPT = cotrimoxazole preventive therapy; ART = antiretroviral therapy; TB = tuberculosis; VCT = voluntary counseling and
testing; OR = odds ratio; CI = confidence interval.
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Table 3 Factors associated with Health system delays in accessing TB treatment services
Characteristic (N = 383) Health system delay > 4 days*
n (%) OR (95% CI) Adjusted OR (95% CI)
Age in years
18 – 25 9 (17.3) Reference Reference
26 – 44 84 (34.4) 2.51 (1.08-5.84) 3.30 (1.16-9.37)
45 – 54 18 (32.4) 2.30 (0.85-6.22) 3.57 (1.09-11.72)
≥55 7 (20.9) 1.26 (0.38-4.18) 2.66 (0.61-11.57)
Type of diagnostic test
Direct smear microscopy 110 (30.4) Reference Reference
Gene Xpert 7 (35.6) 1.27 (0.56-2.85) 0.21 (0.07-0.66)
Sex
Female 61 (35.6) Reference Reference
Male 56 (26.6) 0.66 (0.41-1.06) 0.47 (0.23-0.96)
Type of health facility
District/mission hospital 48 (20.5) Reference Reference
Provincial hospital 12 (64.6) 7.08 (2.81-17.88) 14.15 (4.58-43.69)
Urban municipal 37 (50.1) 3.89 (2.21-6.86) 6.9 (2.41-19.82)
Rural primary healthcare facility 21 (37.6) 2.33 (1.19-4.58) 2.67 (1.18-6.07)
TB Diagnosing centre on site
Yes 71 (25.5) Reference Reference
No 43 (45.8) 2.48 (1.53-4.02) 1.41 (0.59-3.36)
HIV status
Not tested 2 (33.5) Reference Reference
HIV-negative 38 (27.0) 0.73 (0.13-4.11) 0.72 (0.06-8.97)
HIV-positive, not yet on ART 20 (28.0) 0.77 (0.13-4.52) 0.70 (0.06-8.99)
HIV-positive, on ART/CPT 55 (34.5) 1.04 (0.19-5.78) 1.37 (0.11-17.04)
Residence
Urban 43 (37.6) Reference Reference
Rural 74 (27.9) 0.81 (0.54-1.22) 0.95 (0.71-1.29)
History of smoking
Never 80 (29.9) Reference Reference
Current smoker 7 (25.1) 0.79 (0.29-2.14) 1.58 (0.45-5.63)
Quit smoking 29 (34.2) 1.22 (0.70-2.12) 0.86 (0.39-1.89)
History of alcohol use
Never 64 (30.1) Reference Reference
Current drinker 5 (18.6) 0.53 (0.20-1.37) 0.40 (0.11-1.42)
Quit alcohol use 46 (34.7) 1.23 (0.74-2.05) 1.50 (0.69-3.26)
Took traditional medicine
No 109 (31.3) Reference Reference
Yes 9 (24.6) 0.72 (0.31-1.65) 0.66 (0.28-1.57)
Took self-medication from pharmacy
No 98 (29.2) Reference Reference
Yes 20 (41.3) 1.71 (0.90-3.23) 1.68 (0.72-3.93)
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in Zimbabwe, TB treatment services are only offered in
public health facilities hence those that are suspected of
TB or diagnosed with TB in private health care facilities
are referred to public health facilities which could either be
missionary, local authority or government health facilities.
Conclusion
This study has assessed the extent of TB treatment
delays in a country with a high HIV-TB burden, an
important issue that relates to individual patient outcomes
and TB transmission in the community. Patient delays were
found to be moderately high, suggesting the need for in-
creased advocacy, communication and social mobilization
efforts targeted at informing the general population to
seek health services early when they experience symp-
toms suggestive of TB. There is also need for engage-
ment and training of pharmacy staff so that they can
accurately identify people with TB-like symptoms and
effectively explain to them that TB diagnosis and treat-
ment are offered for free at public health institutions. A
programme of this nature has been piloted in Cambodia
and has shown positive results [39].
Table 3 Factors associated with Health system delays in accessing TB treatment services (Continued)
Health care visits prior to diagnosis
1 46 (26.8) Reference Reference
2 40 (33.5) 1.38 (0.79-2.41) 1.82 (0.93-3.53)
3 10 (25.2) 0.92 (0.39-2.15) 0.99 (0.33-2.96)
≥4 20 (43.9) 2.14 (1.06-4.34) 2.24 (1.02-4.94)
Time taken to reach health facility
<30 minutes 52 (34.3) Reference Reference
30mins - 1 hour 33 (33.1) 0.95 (0.52-1.71) 1.38 (0.65-2.93)
>1 hour 32 (25.4) 0.65 (0.37-1.15) 1.03 (0.46-2.27)
Distance to health facility (in km)
≤5 44 (36.4) Reference Reference
6 – 15 17 (26.7) 0.64 (0.32-1.27) 0.78 (0.32-1.88)
16 – 30 18 (32.9) 0.86 (0.41-1.78) 1.84 (0.68-4.98)
≥30 15 (16.5) 0.35 (0.16-0.75) 0.51 (0.20-1.29)
Difficulty in accessing transport to health centre
No 21 (32.6) Reference Reference
Yes 96 (30.3) 1.14 (0.60-2.19) 1.00 (0.64-1.57)
Total 118 (30.7) - -
*Health system delay was defined as a period >4 days from first encounter with health worker to date of starting TB treatment.
DOT = directly observed treatment; HIV = human immunodeficiency virus; CPT = cotrimoxazole preventive therapy; ART = antiretroviral therapy; TB = tuberculosis,
VCT = voluntary counseling and testing.
Figure 1 Total delay in weeks between onset of TB-related symptoms and treatment of TB.
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On the other hand, health system delays were not
common, suggesting an efficient TB programme. Better
understanding about why some patients have repeated
visits to health facilities is needed. We also recommend
more qualitative studies to elicit patient responses on
why patient delays were associated with access to rural
primary health facilities and also why health system de-
lays where linked to older age and being female. Whilst
our study findings are generalizable to those patients
with microbiologically confirmed PTB, they are not
representative of the HIV patient population which
largely has smear negative TB and among whom delays
are likely to be much more complex, longer, and more
difficult to address. Hence a study specific to this popula-
tion is also necessary.
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